CRN Wessex funding model
Purpose of the model
The model is based on a number of basic principles to:
(a) ensure the most effective and efficient use of public money
(b) distribute funding allocation to best effect in pursuance of the NIHR CRN High Level Objectives
(c) ensure that funding is provided for all eligible costs, as defined by DHSC guidance documents ‘Attributing the cost of health and social care Research & Development (AcoRD)’ and ‘Eligibility Criteria for NIHR CRN Support’, incurred by partner organisations conducting NIHR CRN Portfolio research.
(d) provide funding that reflects the volume and complexity of clinical research activity in the geographical footprint of Wessex.
(e) incentivise partners to conduct research and to meet the research delivery standards defined by the NIHR CRN High Level Objectives.
How the model is agreed
The CRN Wessex Chief Operating Officer and Clinical Director consult with a working group formed from partner organisations to review the model against the guiding principles and amend the model as required on an annual basis. The proposed model is reviewed and approved by the CRN Wessex Executive Group, Partnership Group and the Board of the host organisation University Hospital Southampton NHS Foundation Trust. Final allocations to the six components described below are decided once the final allocation is announced by the NIHR CRN CC in Q4 of the preceding FY.
Components of the model
Core funding allocations to partners reflect the volume and complexity of the clinical research activity . To maintain year on year stability there is a safety net of a cap and collar of -/+ 5%. To promote growth there is a minimum uplift of £25K per annum for an organisation receiving uplift in funding to support smaller partners to grow.
To incentivise partners to achieve the NIHR CRN High Level Objectives there is a performance premium. The payment is calculated on volume of activity and percentage of local target achieved. There is additional recognition for sites that recruit the first global patients into international pharmaceutical studies.
The network facilitates research across a wide geographical footprint of Wessex. The core team leads on regional activities to support the partners in pursuit of the high level objectives and is a mandated part of the research infrastructure.
This supports within year unforeseen eligible support costs that arise.
|Core funding to partners||80%|
|Performance premium to partners||3%|
Any enquiries regarding the LCRN funding allocations should be emailed to Rebecca McKay.